Morepen Laboratories Releases Q2 FY26 Investor Presentation with Mixed Financials
Morepen Laboratories released its Q2 FY26 investor presentation. Standalone revenue was ₹374 crore, with PAT at ₹14 crore. Consolidated PAT significantly increased to ₹41 crore, despite mixed revenue performance.
The impact is medium as financial results are important for investors. However, the mixed performance (revenue dips in some areas vs. profit increases in others) prevents it from being a high impact, despite detailed operational insights.
The sentiment is neutral due to mixed financial results: standalone and consolidated revenues show a slight decline year-on-year or quarter-on-quarter, but there's a notable increase in standalone and consolidated EBITDA and PAT quarter-on-quarter. Medical Devices H1 revenue also grew.
Morepen Laboratories Limited has released its Investor Presentation for the second quarter and half year ended 30th September 2025 (Q2 FY26). * Standalone Financial Performance (Q2 FY26 vs Q1 FY26): * Gross Revenue decreased to ₹374 crore from ₹395 crore. * EBITDA increased to ₹33 crore from ₹23 crore. * PAT increased to ₹14 crore from ₹8 crore. * Consolidated Financial Performance (Q2 FY26 vs Q1 FY26): * Gross Revenue decreased to ₹416 crore from ₹430 crore. * EBITDA increased to ₹35 crore from ₹29 crore. * PAT significantly increased to ₹41 crore from ₹11 crore. * Year-on-Year Standalone Revenue: * Q2 FY26 revenue was ₹374 crore, compared to ₹388 crore in Q2 FY25. * H1 FY26 revenue was ₹770 crore, compared to ₹777 crore in H1 FY25. * Business Segments Contribution (Q2 FY26): Pharma Business (API+Rx) accounted for 66%, and Medical Devices (Point of Care) for 34% of the overall business. * Medical Devices Segment: * H1 FY26 revenue grew to ₹287 crore from ₹271 crore in H1 FY25. * Q2 FY26 revenue was ₹126 crore, compared to ₹133 crore in Q2 FY25. * Key products include Thermometers, Nebulisers, Pregnancy Kits, Ortho supports, Blood Glucose meters, and BP Monitors. * The company is a market leader for BP Monitors, holding the #1 position. * It boasts a happy customer base of 16.1 million for glucometers. * Pharma Business Segment: * H1 FY26 revenue was ₹483 crore, compared to ₹506 crore in H1 FY25. * Q2 FY26 revenue increased to ₹248 crore from ₹235 crore in Q1 FY26. * API revenue for Q2 FY26 was ₹219 crore, up from ₹205 crore in Q1 FY26. * Key API products by share include Atorva (27.7%), Lorata+Des (24.4%), and Monte (13%). * API continent-wise share for Q2 FY26 was Europe (31.6%), India (28.5%), Asia (21.7%), USA (14.8%), and S. America (3.4%). * Rx: Branded Formulation revenue for Q2 FY26 increased to ₹29 crore from ₹24 crore in Q2 FY25, showing consistent growth with new products.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.